Aerie Pharma (AERI) CEO Departure Does Not Have Implications for Performance - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $26.00 price target on Aerie Pharma (NASDAQ: AERI) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
